Several forms of a paraoxonase enzyme provide different degrees of protection against organophosphate chemicals.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis
BMC Musculoskeletal Disorders Open Access 19 November 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hyde, E.G. & Carmichael, W.W. Anatoxin-a (S), a naturally occurring organo-phosphate, is an irreversible active site-directed inhibitor of acetyl-cholinesterase (EC 3.1.1. 7). J. Biochem. Toxicol. 6, 195–201 (1991).
La Du, B.N. Human serum paraoxonase/arylesterase. in Pharmacogenetics of Drug Metabolism (ed. Karlow, W.) 51–91 (Pergamon, New York, 1992).
Davies, H.G. et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet. 14, 334–336 (1996).
Broomfield, C.A. & Ford, K.W. Hydrolysis of nerve agents by plasma enzymes. in Cholinesterases (ed Massoulie, J.). 307 (American Chemical Society, Washington, DC, 1991).
St Clair, M.H. et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557–1559 (1991).
Adkins, S., Can, K.N., Mody, M. & La Du, B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52, 598–608 (1993).
Humbert, R. et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet. 3, 73–76 (1993).
Watson, A.D. et al. Protective effect of high density lipoprotein-associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96, 2882–2891 (1995).
Sorenson, R.C., Primo-Parmo, S.L., Camper, S.A. & La Du, B.N. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics 30, 431–438 (1995).
Primo-Parmo, S.L., Sorenson, R.C., Teiber, J. & The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33, 498–507 (1996).
Ruiz, J.H. et al. The polymorphism (Gln-Argl92) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin-dependent diabetic patients. Lancet 346, 869–872 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
La Du, B. Structural and functional diversity of paraoxonases. Nat Med 2, 1186–1187 (1996). https://doi.org/10.1038/nm1196-1186
Issue Date:
DOI: https://doi.org/10.1038/nm1196-1186
This article is cited by
-
Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis
BMC Musculoskeletal Disorders (2014)
-
Plasma paraoxonase 1 arylesterase activity in d-galactose-induced aged rat model: correlation with LDL oxidation and redox status
Aging Clinical and Experimental Research (2014)
-
Correlation of Paraoxonase1 Activities with Birth Weight
The Indian Journal of Pediatrics (2014)
-
Paraoxonase 1 Activity in Chylomicrons and VLDL: The Effect of Type 2 Diabetes and Meals Rich in Saturated Fat and Oleic Acid
Lipids (2012)
-
Synergism between paraoxonase Arg 192 and the angiotensin converting enzyme D allele is associated with severity of coronary artery disease
Molecular Biology Reports (2012)